Innova Captab IPO

Innova Captab Limited

₹14,058 /33 sharesMinimum Investment

Innova Captab IPO Listing Details

Listed OnIssue PriceListing PriceListing Gains
BSE & NSE₹448.00₹456.00₹8.00 (1.79%)

Innova Captab IPO Details

Bidding DatesMin. InvestmentLot SizePrice Range
21 Dec ‘23 - 26 Dec ‘23₹14,05833₹426 - ₹448
Issue SizeIPO Doc
570.00Cr
RHP PDF

Subscription rate

Qualified Institutional Buyers116.73x
Non-Institutional Investor64.94x
Retail Individual Investor17.15x
Total55.26x

About the company

Innova Captab is a pharma company involved in research, development, manufacturing, drug distribution, marketing, and exports. The company started its journey by offering contract development and manufacturing organization (CDMO) services to various Indian pharmaceutical companies, alongside its domestic and international branded generics businesses. It has 2 manufacturing facilities in Baddi, Himachal Pradesh, and is planning for a new facility in Jammu. Innova Captab has expanded its portfolio to over 600 diverse generic products, marketed under its own brands in India through a network of 5,000 distributors and 150,000 retail pharmacies. The company also brands generic products to numerous countries. Offering a range of products from oral solids to injectables and using new technologies like nano technology, Innova Captab caters to both acute and chronic therapeutic areas.;
Founded in
2005
Managing director
Mr. Vinay Kumar Lohariwala
Parent organisation
Innova Captab Limited

Strength and risks

Strengths
Risks
The company has a diverse range of over 600 products across various therapeutic areas, including complex formulations like modified and sustained-release forms and tablets in capsules. This wide-ranging portfolio enables them to cater to a broad spectrum of healthcare needs.
Innova Captab emphasizes robust in-house R&D, which aids in attracting CDMO customers and growing its branded generic portfolio. They have a dedicated R&D facility, recognized by the Department of Scientific and Industrial Research, India.
The company operates state-of-the-art manufacturing facilities which are certified for Good Manufacturing Practices.
Innova Captab has expanded its international presence, exporting branded generics to numerous countries.
One of the fastest growing CDMOs in the Indian pharmaceutical formulations market, as per a CRISIL report.
In the financial year 2023, the company had 182 CDMO customers including Cipla, Glenmark Pharma, Wockhardt, Corona Remedies, Emcure Pharma, Lupin and Mankind Pharma.
According to CRISIL Research, the company ranked 3rd among its peers in terms of finished tablet and capsule manufacturing capacity in India.

Financials

*All values are in Rs. Cr
No Graph Data To Display

Application details

Apply asPrice bandApply upto
Regular426 - 448₹2 Lakh
High Networth Individual426 - 448₹2 - 5 Lakh
For Innova Captab IPO, eligible investors can apply as Regular.
ⓒ 2016-2024 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 5.1.9
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  GROWWMF |  SBI |  AXIS |  HDFC |  UTI |  NIPPON INDIA |  ICICI PRUDENTIAL |  TATA |  KOTAK |  DSP |  CANARA ROBECO |  SUNDARAM |  MIRAE ASSET |  IDFC |  FRANKLIN TEMPLETON |  PPFAS |  MOTILAL OSWAL |  INVESCO |  EDELWEISS |  ADITYA BIRLA SUN LIFE |  LIC |  HSBC |  NAVI |  QUANTUM |  UNION |  ITI |  MAHINDRA MANULIFE |  360 ONE |  BOI |  TAURUS |  JM FINANCIAL |  PGIM |  SHRIRAM |  BARODA BNP PARIBAS |  QUANT |  WHITEOAK CAPITAL |  TRUST |  SAMCO |  NJ

ABOUT GROWW